A Polytherapy Intervention in an Experimental Traumatic Optic Neuropathy Mouse Model.

Tse DT, Wang H, Tao W, O'Brien RC, Tse BC, Pelaez D

Ophthalmic plastic and reconstructive surgery13 Feb 2025

PMID39945348DOI10.1097/iop.0000000000002917PepBankPUB-39945348

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Elamipretide (SS-31).

01AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Efficacy outcome
In mice with traumatic optic neuropathy, pattern ERG amplitudes in the polytherapy group did not differ significantly from baseline at any time point except week 8.
In plain wordsIn mice with optic nerve injury, retinal signals stayed near baseline with a multi-drug regimen including elamipretide, except at week 8.
Peptide
Elamipretide (SS-31)
Outcome
No significant changePattern ERG amplitude in treatment group
Study
mousen = 10
sonication-induced traumatic optic neuropathy
Comparator
Baseline
Outcome group
Neuroprotection · Eye
Source sentences
Summary
Apart from week 8, the amplitudes in the treatment group did not significantly differ from the baseline at any time point.
4 context sentences(design, population, supporting numbers)
Summary · context
Twenty C57BL/6J mice were subjected to sonication-induced traumatic optic neuropathy injury.
Summary · context
The control group (n = 10) received intravitreal, retrobulbar, and subcutaneous phosphate buffered saline injections on days 0 and 3 (no repeat retrobulbar vehicle).
Summary · context
On day 0, the treatment group (n = 10) received injections of intravitreal interleukin-1 receptor antagonist with ketamine, retrobulbar ropivacaine, and subcutaneous etanercept.
Summary · context
On day 3, intravitreal pan-ephrin receptor antagonist peptide and subcutaneous elamipretide and etanercept injections were given.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-3994534804
02AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Efficacy outcome
In mice with traumatic optic neuropathy, an early polytherapy regimen that included elamipretide gave higher retinal ganglion cell density than control at 12 weeks.
In plain wordsIn mice with optic nerve injury, a multi-drug regimen including elamipretide preserved more retinal nerve cells than control.
Peptide
Elamipretide (SS-31)
Outcome
IncreaseRetinal ganglion cell density at 12 weeks
Study
mousen: not reported in source
sonication-induced traumatic optic neuropathy
Comparator
Control (PBS injections)
Outcome group
Neuroprotection · Eye
Measurements
RGC density
553.97 cells/mm2
treatment
RGC density
413.37 cells/mm2
control
Source sentences
Summary
At 12 weeks, the averaged retinal ganglion cell density count in the control group was lower (413.37 ± 41.77 cells/mm 2 ) compared with treatment (553.97 ± 18.00 cells/mm 2 ; p < 0.001) and naive (595.94 ± 30.67cells/mm 2 ; p < 0.001) groups.
4 context sentences(design, population, supporting numbers)
Summary · context
Twenty C57BL/6J mice were subjected to sonication-induced traumatic optic neuropathy injury.
Summary · context
The control group (n = 10) received intravitreal, retrobulbar, and subcutaneous phosphate buffered saline injections on days 0 and 3 (no repeat retrobulbar vehicle).
Summary · context
On day 0, the treatment group (n = 10) received injections of intravitreal interleukin-1 receptor antagonist with ketamine, retrobulbar ropivacaine, and subcutaneous etanercept.
Summary · context
On day 3, intravitreal pan-ephrin receptor antagonist peptide and subcutaneous elamipretide and etanercept injections were given.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-3994534801
03AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Efficacy outcome
In mice with traumatic optic neuropathy, an early polytherapy regimen that included elamipretide preserved ganglion cell complex layer thickness better than control at 12 weeks.
In plain wordsIn mice with optic nerve injury, a multi-drug regimen including elamipretide kept the retinal cell layer thicker than control.
Peptide
Elamipretide (SS-31)
Outcome
IncreaseGanglion cell complex layer thickness at 12 weeks
Study
mousen: not reported in source
sonication-induced traumatic optic neuropathy
Comparator
Control (PBS injections)
Outcome group
Neuroprotection · Eye
Measurements
GCC thickness
61 μm
treated
GCC thickness
49.29 μm
control
Source sentences
Summary
Ganglion cell complex layer thicknesses showed control group (49.29 ± 5.48 μm) thinner than the treated (61.00 ± 2.57 μm; p = 0.004) and naive (67.00 ± 6.12 μm; p = 0.004) groups.
4 context sentences(design, population, supporting numbers)
Summary · context
Twenty C57BL/6J mice were subjected to sonication-induced traumatic optic neuropathy injury.
Summary · context
The control group (n = 10) received intravitreal, retrobulbar, and subcutaneous phosphate buffered saline injections on days 0 and 3 (no repeat retrobulbar vehicle).
Summary · context
On day 0, the treatment group (n = 10) received injections of intravitreal interleukin-1 receptor antagonist with ketamine, retrobulbar ropivacaine, and subcutaneous etanercept.
Summary · context
On day 3, intravitreal pan-ephrin receptor antagonist peptide and subcutaneous elamipretide and etanercept injections were given.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-3994534802
04AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Efficacy outcome
In mice with traumatic optic neuropathy, the polytherapy group did not differ significantly from naive mice at 12 weeks.
In plain wordsIn mice with optic nerve injury, those given a multi-drug regimen including elamipretide did not differ from uninjured mice at 12 weeks.
Peptide
Elamipretide (SS-31)
Outcome
No significant changeTreated versus naive difference at 12 weeks
Study
mousen: not reported in source
sonication-induced traumatic optic neuropathy
Comparator
Naive mice
Outcome group
Neuroprotection · Eye
Source sentences
Summary
No significant difference was seen at 12 weeks between the treated and naive groups.
4 context sentences(design, population, supporting numbers)
Summary · context
Twenty C57BL/6J mice were subjected to sonication-induced traumatic optic neuropathy injury.
Summary · context
The control group (n = 10) received intravitreal, retrobulbar, and subcutaneous phosphate buffered saline injections on days 0 and 3 (no repeat retrobulbar vehicle).
Summary · context
On day 0, the treatment group (n = 10) received injections of intravitreal interleukin-1 receptor antagonist with ketamine, retrobulbar ropivacaine, and subcutaneous etanercept.
Summary · context
On day 3, intravitreal pan-ephrin receptor antagonist peptide and subcutaneous elamipretide and etanercept injections were given.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-3994534803

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
10 Oct 2026, 08:19 UTC
Study results updated
Version 1
9 Oct 2026, 02:47 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.